Processing

Please wait...

Settings

Settings

Goto Application

1. WO2014174747 - THERAPEUTIC AGENT FOR EYEGROUND DISEASE

Publication Number WO/2014/174747
Publication Date 30.10.2014
International Application No. PCT/JP2014/001123
International Filing Date 03.03.2014
IPC
A61K 31/496 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
A61P 27/02 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
27Drugs for disorders of the senses
02Ophthalmic agents
CPC
A61K 31/496
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
A61K 31/551
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
55having seven-membered rings, e.g. azelastine, pentylenetetrazole
551having two nitrogen atoms, e.g. dilazep
A61K 47/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
08containing oxygen, ; e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
A61K 9/0046
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
0012Galenical forms characterised by the site of application
0046Ear
A61K 9/0048
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
0012Galenical forms characterised by the site of application
0048Eye, e.g. artificial tears
C07D 401/12
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02containing two hetero rings
12linked by a chain containing hetero atoms as chain links
Applicants
  • 国立大学法人九州大学 KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION [JP]/[JP]
  • 興和株式会社 KOWA COMPANY, LTD. [JP]/[JP]
Inventors
  • 石橋 達朗 ISHIBASHI, Tatsuro
  • 中尾 新太郎 NAKAO, Shintaro
  • 有田 量一 ARITA, Ryoichi
  • 水野 憲 MIZUNO, Ken
  • 土浦 暁史 TSUCHIURA, Akifumi
Agents
  • 佐伯 憲生 SAEKI, Norio
Priority Data
2013-09085124.04.2013JP
Publication Language Japanese (JA)
Filing Language Japanese (JA)
Designated States
Title
(EN) THERAPEUTIC AGENT FOR EYEGROUND DISEASE
(FR) AGENT THÉRAPEUTIQUE POUR MALADIE DU FOND DE L'OEIL
(JA) 眼底疾患治療剤
Abstract
(EN)
Provided is a medicine for preventing or treating eyeground diseases, in particular, diabetic retinopathy or age-related macular degeneration. This preventive or therapeutic agent for eyeground diseases comprises, as an active ingredient, (S)-(-)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4- homopiperazine or a salt thereof, or a solvate thereof.
(FR)
L'invention concerne un médicament pour prévenir ou traiter des maladies du fond de l'oeil, en particulier, une rétinopathie diabétique ou une dégénérescence maculaire liée à l'âge. Cet agent préventif ou thérapeutique destiné aux maladies du fond de l'oeil comprend, en tant que principe actif, du (S)-(-)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4- homopiperazine ou un sel de celui-ci, ou un solvate de celui-ci.
(JA)
 眼底疾患、特に糖尿病網膜症又は加齢黄斑変性の予防又は治療のための薬剤の提供。 (S)-(-)-1-(4-フルオロ-5-イソキノリンスルホニル)-2-メチル-1,4-ホモピペラジン若しくはその塩又はそれらの溶媒和物を有効成分とする眼底疾患の予防又は治療剤。
Other related publications
Latest bibliographic data on file with the International Bureau